Mindrank AI Co. Ltd. and Mindrank Therapeutics (Suzhou) New Drug Research have disclosed new Wee1-like protein kinase (Wee1) and/or tyrosine-protein kinase Yes (YES1) inhibitors potentially useful for the treatment of cancer, inflammation and autoimmune diseases.